Already a member? Click here to login.
Already a member? Click here to login.
Following a review by the ADEA CDE Advisory Group, advice for CDEs about counting clicks when using the 1mg OZEMPIC® pen has been published below and in the clinical guidelines section of the ADEA website.
ADEA understands that due to a shortage of availability of OZEMPIC® pens (0.25mg and 0.5mg), people living with diabetes are being advised that if the 1mg pen is the only available option, they should use it and count audible clicks to achieve the appropriate dose (e.g. using a 1mg pen and counting 18 clicks for a 0.25 mg dose).
It is important to note that the manufacturer Novo Nordisk has provided the following advice: Novo Nordisk recommends that only marked doses of 0.25mg or 0.5mg be selected for the OZEMPIC® 0.25mg/0.5mg pen and marked dose of 1mg be selected for the OZEMPIC® 1mg pen. Using unmarked doses could result in inaccurate or inconsistent dosing.
ADEA does not recommend counting clicks due to the risks and potential for errors. Counting clicks is against the manufacturer’s recommended usage and raises concerns regarding scope of practice, off-label usage, and inconsistencies with the dosage or volume provided. ADEA recommends adherence to manufacturer guidelines and instructions and exploring other strategies.
Download the advice as a PDF here.
Following a review by the ADEA CDE Advisory Group, advice for CDEs about counting clicks when using the 1mg OZEMPIC® pen has been published below and in the clinical guidelines section of the ADEA website.
ADEA understands that due to a shortage of availability of OZEMPIC® pens (0.25mg and 0.5mg), people living with diabetes are being advised that if the 1mg pen is the only available option, they should use it and count audible clicks to achieve the appropriate dose (e.g. using a 1mg pen and counting 18 clicks for a 0.25 mg dose).
It is important to note that the manufacturer Novo Nordisk has provided the following advice: Novo Nordisk recommends that only marked doses of 0.25mg or 0.5mg be selected for the OZEMPIC® 0.25mg/0.5mg pen and marked dose of 1mg be selected for the OZEMPIC® 1mg pen. Using unmarked doses could result in inaccurate or inconsistent dosing.
ADEA does not recommend counting clicks due to the risks and potential for errors. Counting clicks is against the manufacturer’s recommended usage and raises concerns regarding scope of practice, off-label usage, and inconsistencies with the dosage or volume provided. ADEA recommends adherence to manufacturer guidelines and instructions and exploring other strategies.
Download the advice as a PDF here.
